

ADR Focus by Elizabeth Rudy, DVM, RPh

Update: Drugs That Cause Osteoporosis

References

1. Gruver RA. Current approaches to preventing osteoporosis. *JAAPA* 2004;17(11):37-41.
2. Parsons LC. Osteoporosis: incidence, prevention, and treatment of the silent killer. *Nurs Clin N Am* 2005;40(1):129-133.
3. Tannirandorn P, Epstein S. Drug-induced bone loss. *Osteoporos Int* 2000;11:637-659.
4. Lawson J. Drug-induced metabolic bone disorders. *Semin Musculoskelet Radiol* 2002;6(4):285-297.
5. Osteoporosis. *Prescriber's Letter* August 2004.
6. Encke J, Stremmel W, Sauer P. Immunosuppression and modulation in liver transplantation. *Nephrol Dial Transplant* 2004;19(suppl 4):iv22-25.
7. Sprague SM, Josephson MA. Bone disease after kidney transplantation. *Semin Nephrol* 2004;24(1):82-90.
8. Drezner MK. Treatment of anticonvulsant drug-induced bone disease. *Epilepsy Behav* 2004;5(Suppl 2):S41-47.
9. Pack AM, Morrell MJ. Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms and therapeutic implications. *CNS Drugs* 2001;15(8):633-642.
10. Hummer M, et al. Osteoporosis in patients with schizophrenia. *Am J Psychiatry* 2005;162:162-167.
11. Meaney AM, O'Keane V. Reduced bone mineral density in patients with schizophrenia receiving prolactin raising anti-psychotic medication. *J Psychopharmacol* 2003;17(4):455-458.
12. Buckley LM, et al. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. *J Rheumatol* 1997;24:1489-1494.
13. Townsend MF, et al. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. *Cancer* 1997;79:545-550.
14. Wooltorton E. Medroxyprogesterone acetate (Depo-Provera) and bone mineral density loss. *JAMC* 2005;172(6):746.
15. Hawkins D, Evans J. Minimising the risk of heparin-induced osteoporosis during pregnancy. *Expert Opin Drug Saf* 2005;4(3):583-590.
16. Sivakumaran M, et al. Osteoporosis and vertebral collapse following low-dose, low molecular weight heparin therapy in a young patient. *Clin Lab Haematol* 1996;18:55-57.
17. Robinson, et al. Metabolic bone disease after chronic antacid administration in an infant. *Ann Pharmacother* 2004;38(2):265-268.
18. New Safety Information on the Use of DEPO-PROVERA (medroxyprogesterone acetate suspension for injection, 150mg IM) associated with Bone Mineral Density Changes June 30, 2005. http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/depo-provera_pa_ap_e.pdf

A University of Washington Drug Information Center publication
Distributed monthly by authority of the Pharmacy and Therapeutics Committee
Editor: Nelda A. Murri, Pharm.D. (206) 598-6612 – Asst. Editor: Elizabeth Rudy, D.V.M., R.Ph.
Department of Pharmacy Services / School of Pharmacy

Copyright © 2005 by the University of Washington
Also published on the World Wide Web at <http://uw.pnrx.org/therapyTopics.asp>
No material may be reproduced in whole or in part without written permission from the editor.